Svetlana Pack
Staff Scientist
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (13)
Indeterminate dendritic cell histiocytosis (IDCH) is a rare and poorly understood entity characterized by accumulation of CD1a+/S100+ histiocytes (as Langerhans cell histiocytosis [LCH]) but with reduced-absent expression of Langerin/CD207. We assembled 43 cases of IDCH (defined by CD1a+/CD207<20% immunophenotypic profile) examining the clinical, pathologic, and molecular landscape. Median age at presentation was 70 years (interquartile range, 44-80) with cutaneous (31/43; 72%) and nodal (11/43; 26%) involvement predominating. Eighteen (42%) individuals had an associated nonhistiocytic hematopoietic neoplasm (“secondary” IDCH) whereas 7 of 43 (16%) had a concurrent non-IDCH histiocytosis (“mixed” histiocytosis). Most cases exhibited morphology indistinguishable from LCH but with a CD1c+/CSF1R(CD115)− phenotype, mirroring the signature of normal indeterminate cells and conventional DC type 2. Mutational analysis revealed frequent KRAS (13/32; 41%) and BRAF p.V600E (11/36, 31%) mutations that were nearly mutually exclusive. RNA-sequencing analysis uncovered ETV3::NCOA2 fusion in 6 other patients presenting as a sole genetic alteration without any other concurrent histiocytic or hematopoietic neoplasm. BRAF and MAP2K1 alterations were significantly associated with partial/retained (1%-20%) Langerin expression (P = .005) and mixed histiocytosis (P = .002). Remarkably, myeloid alterations (DNMT3A, TET2, and SRSF2) co-occurred in IDCH tissues of several individuals. Paired sequencing of IDCH and concurrent non-IDCH hematopoietic neoplasm in 4 individuals revealed shared mutations. Age at diagnosis and any nodal involvement at diagnosis predicted inferior overall survival, but BRAF/RAS pathway alterations did not affect outcome. These data have implications for the diagnostic evaluation, classification, and therapeutic management of IDCH.
Year:
2024
Phospho-MET expression is an indicator of MET activity post-osimertinib treatment; and proposed clinical flow diagram for treating EGFR -mutant NSCLC with evidence of MET pathway activation after osimertinib resistance. Representative phospho-MET IHC, MET FISH images and MET FISH scoring from pre- and post-osimertinib resistant tumors from patient LAT028 (multiple spatially heterogenous post-osimertinib resistant tumors shown; A ) and from patient LAT021 ( B ). Scale bars, 50 µm. C, Clinical flow diagram for osimertinib-resistant EGFR -mutant NSCLC with evidence of MET pathway activation.
Year:
2024
Heterogeneity in MET polysomy and MET amplification in osimertinib-resistant EGFR-mutant NSCLC. A, Representative phospho-MET IHC (several are reused from Fig. 2D ), MET FISH images and MET FISH scoring from PDXs with MET polysomy. B, Representative phospho-MET IHC, MET FISH images and MET FISH scoring from longitudinally collected tumor samples from patient LAT006 at first progression on osimertinib, second progression after osimertinib rechallenge, and upon further progression on chemoimmunotherapy. Scale bars, 50 µm.
Year:
2024
Efficacy and determinants of response to osimertinib and savolitinib combination among osimertinib-resistant EGFR-mutant NSCLC PDX models with spatially and temporally heterogenous MET pathway activation. Tumor growth inhibition studies in MET polysomy ( A ) and MET amplified ( B ) PDXs. Dashed vertical lines delineate when treatment was stopped. Asterisks signify statistical significance between osimertinib and savolitinib combination and osimertinib alone treatment arms. P values were calculated by t test. P values C, Association between response to osimertinib and savolitinib combination and IHC features (phospho-MET, c-MET), copy number and FISH parameters (number of MET copies and MET/CEP7 ratio). Response is defined as >25 days until reaching tumor size endpoint in osimertinib and savolitinib combination compared with osimertinib treatment alone. Individual circles represent a unique tumor for each represented PDX model. D, Representative c-MET and phospho-MET IHC images of PDX tumors with and without response to osimertinib and savolitinib combination. Scale bars, 50 µm.
Year:
2024
MET pathway activation is one of the most common mechanisms of resistance to osimertinib in EGFR -mutant non–small cell lung cancer (NSCLC). We previously demonstrated spatial and temporal heterogeneity in MET pathway activation upon osimertinib resistance in EGFR -mutant NSCLC; however, the functional relevance of these findings is unclear. Here, we generated 19 patient-derived xenografts (PDX) from 9 patients with multi-region and temporal sampling of osimertinib-resistant tumor tissue from patients with EGFR -mutant NSCLC. MET pathway activation was a putative mechanism of osimertinib resistance in 66% ( n = 6/9) patients from whom PDXs were generated. Significant spatial and temporal heterogeneity in MET pathway activation was evident. Osimertinib-resistant PDXs with MET amplification by FISH (defined as MET/CEP7 ratio ≥2.0 or mean MET ≥ 6.0 copies/cell) and high-level phospho-MET, but not c-MET expression, had better responses to osimertinib and savolitinib combination than to osimertinib alone. MET polysomy tumors by FISH from both PDXs and patients had evidence of subclonal phospho-MET expression. Select MET polysomy PDX tumors with phospho-MET expression responded better to osimertinib and savolitinib combination than MET polysomy PDX tumors without phospho-MET expression. Our results suggest osimertinib and savolitinib combination is most effective for osimertinib-resistant EGFR -mutant tumors with MET pathway activation as evidenced by phospho-MET. As subclonal MET amplification may be evident in MET polysomy tumor progression, MET polysomy warrants close clinical follow-up with phospho-MET IHC in parallel with FISH diagnostic. Significance: Using a novel cohort of in vivo PDX models of MET pathway activation with acquired resistance to osimertinib in EGFR-mutant lung cancer, we demonstrate that phospho-MET may be a clinically relevant assay to guide treatment selection with osimertinib and savolitinib combination. In addition, our work shows that patients with MET polysomy tumors may have subclonal MET amplification and therefore require close follow up for the use of osimertinib and savolitinib combination.
Year:
2024
Phospho-MET expression is an indicator of MET activity post-osimertinib treatment; and proposed clinical flow diagram for treating EGFR -mutant NSCLC with evidence of MET pathway activation after osimertinib resistance. Representative phospho-MET IHC, MET FISH images and MET FISH scoring from pre- and post-osimertinib resistant tumors from patient LAT028 (multiple spatially heterogenous post-osimertinib resistant tumors shown; A ) and from patient LAT021 ( B ). Scale bars, 50 µm. C, Clinical flow diagram for osimertinib-resistant EGFR -mutant NSCLC with evidence of MET pathway activation.
Year:
2024
Heterogeneity in MET polysomy and MET amplification in osimertinib-resistant EGFR-mutant NSCLC. A, Representative phospho-MET IHC (several are reused from Fig. 2D ), MET FISH images and MET FISH scoring from PDXs with MET polysomy. B, Representative phospho-MET IHC, MET FISH images and MET FISH scoring from longitudinally collected tumor samples from patient LAT006 at first progression on osimertinib, second progression after osimertinib rechallenge, and upon further progression on chemoimmunotherapy. Scale bars, 50 µm.
Year:
2024
Osimertinib and savolitinib combination suppresses AKT signaling in MET amplified osimertinib-resistant EGFR-mutant NSCLC PDXs. EGFR and MET pathway protein expression in MET amplified ( A ) and MET polysomy ( B ) LAT006 PDXs treated with either vehicle, osimertinib, savolitinib, and osimertinib plus savolitinib. Bar graphs show the relative quantification of phosphorylated proteins normalized to total protein expression in MET amplified ( C ) and MET polysomy ( D ) LAT006 PDXs.
Year:
2024
MET pathway activation is one of the most common mechanisms of resistance to osimertinib in EGFR -mutant non–small cell lung cancer (NSCLC). We previously demonstrated spatial and temporal heterogeneity in MET pathway activation upon osimertinib resistance in EGFR -mutant NSCLC; however, the functional relevance of these findings is unclear. Here, we generated 19 patient-derived xenografts (PDX) from 9 patients with multi-region and temporal sampling of osimertinib-resistant tumor tissue from patients with EGFR -mutant NSCLC. MET pathway activation was a putative mechanism of osimertinib resistance in 66% ( n = 6/9) patients from whom PDXs were generated. Significant spatial and temporal heterogeneity in MET pathway activation was evident. Osimertinib-resistant PDXs with MET amplification by FISH (defined as MET/CEP7 ratio ≥2.0 or mean MET ≥ 6.0 copies/cell) and high-level phospho-MET, but not c-MET expression, had better responses to osimertinib and savolitinib combination than to osimertinib alone. MET polysomy tumors by FISH from both PDXs and patients had evidence of subclonal phospho-MET expression. Select MET polysomy PDX tumors with phospho-MET expression responded better to osimertinib and savolitinib combination than MET polysomy PDX tumors without phospho-MET expression. Our results suggest osimertinib and savolitinib combination is most effective for osimertinib-resistant EGFR -mutant tumors with MET pathway activation as evidenced by phospho-MET. As subclonal MET amplification may be evident in MET polysomy tumor progression, MET polysomy warrants close clinical follow-up with phospho-MET IHC in parallel with FISH diagnostic. Significance: Using a novel cohort of in vivo PDX models of MET pathway activation with acquired resistance to osimertinib in EGFR-mutant lung cancer, we demonstrate that phospho-MET may be a clinically relevant assay to guide treatment selection with osimertinib and savolitinib combination. In addition, our work shows that patients with MET polysomy tumors may have subclonal MET amplification and therefore require close follow up for the use of osimertinib and savolitinib combination.
Year:
2024
Osimertinib and savolitinib combination suppresses AKT signaling in MET amplified osimertinib-resistant EGFR-mutant NSCLC PDXs. EGFR and MET pathway protein expression in MET amplified ( A ) and MET polysomy ( B ) LAT006 PDXs treated with either vehicle, osimertinib, savolitinib, and osimertinib plus savolitinib. Bar graphs show the relative quantification of phosphorylated proteins normalized to total protein expression in MET amplified ( C ) and MET polysomy ( D ) LAT006 PDXs.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (6)
Jean Donadieu
MD Ph D
Assistance Publique - Hôpitaux de Paris
Elaine Jaffe
Head, Hematopathology Section
National Cancer Institute
maxime battistella
Assistant professor
Université Paris Diderot
Jean-François Emile
Université de Versailles Saint-Quentin-en-Yvelines
Liqiang Xi
Staff Scientist
National Institutes of Health
Rajaa El Meskini
Head of Immuno-oncology Modeling Core
St. Jude Children's Research Hospital
Make your next move.
Prepare your application
Review drafts before you send them.